Efficacy in CB1 receptor-mediated signal transduction

被引:51
作者
Howlett, AC
机构
[1] N Carolina Cent Univ, Neurosci Drug Abuse Res Program, Julius L Chambers Biomed Biotechnol Res Inst, Durham, NC 27707 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA
关键词
aminoalkylindoles; anandamide; cyclic AMP; Ca2+ channels; CP55940; cerebellar membranes; CB1 receptor (-/-) transgenic mice; G protein-coupled receptors; GTP gamma S binding; levonantradol; radioligand binding assays; receptor immunoprecipitation; Delta(9)-tetrahydrocannabinol; WIN55212-2;
D O I
10.1038/sj.bjp.0705881
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CB1 receptor cellular signal transduction is dependent on the expression of G proteins to which the receptor couples, the potential for precoupling of particular G proteins to the receptors either by scaffolding mechanisms or colocalization in lipid raft domains, and the effector mechanisms that these transducer molecules regulate. This discourse will evaluate studies of efficacy for CB1 receptor-Gi/o activation at the molecular level. Evidence for brain regional differences in CB1 receptor signal transduction efficacy and agonist selectivity for G proteins will be summarized. The possibility that CB1 receptors interact with Gs or Gq will be evaluated, and questions with regard to the constitutive activity and G protein sequestration will be posed.
引用
收藏
页码:1209 / 1218
页数:10
相关论文
共 73 条
[1]   Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs [J].
Abadji, V ;
Lucas-Lenard, JM ;
Chin, CN ;
Kendall, DA .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (05) :2032-2038
[2]  
Adams IB, 1998, J PHARMACOL EXP THER, V284, P1209
[3]   Differential effects of Δ9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice [J].
Baskfield, CY ;
Martin, BR ;
Wiley, JL .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 309 (01) :86-91
[4]  
Bonhaus DW, 1998, J PHARMACOL EXP THER, V287, P884
[5]   A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions [J].
Bouaboula, M ;
Perrachon, S ;
Milligan, L ;
Canat, X ;
RinaldiCarmona, M ;
Portier, M ;
Barth, F ;
Calandra, B ;
Pecceu, F ;
Lupker, J ;
Maffrand, JP ;
LeFur, G ;
Casellas, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (35) :22330-22339
[6]  
Breivogel CS, 2000, J PHARMACOL EXP THER, V295, P328
[7]   Evidence for a new G protein-coupled cannabinoid receptor in mouse brain [J].
Breivogel, CS ;
Griffin, G ;
Di Marzo, V ;
Martin, BR .
MOLECULAR PHARMACOLOGY, 2001, 60 (01) :155-163
[8]   Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity [J].
Breivogel, CS ;
Selley, DE ;
Childers, SR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (27) :16865-16873
[9]  
Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632
[10]   Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain [J].
Burkey, TH ;
Quock, RM ;
Consroe, P ;
Ehlert, FJ ;
Hosohata, Y ;
Roeske, WR ;
Yamamura, HI .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 336 (2-3) :295-298